Health technology assessment + strategy

Development of the value strategy of your products is based on an in-depth understanding of the science, an accurate knowledge of the clinical and reimbursement landscape, and an informed view on the current and future competitive environment. Our senior strategists provide support throughout the product life cycle and across indications, from the pipeline stage through to reimbursement applications and post-submission support.

Our team can help you navigate the HTA world in different settings and provide strategic advice based on global and local requirements, including evidence generation planning and execution and value proposition development and validation. We review and critique client and competitor dossiers and HTA comments with an eye towards achieving the most optimal reimbursement. We also assess in-licensing opportunities and can provide strategic market analysis and environmental scans to lay the groundwork for life cycle activities.

Our strategic consulting services include:

• Early integrated scientific advice
• Market access roadmaps
• Product life cycle planning
• Competitor analysis
• Critical appraisals of HTA submissions to ICER, NICE, CADTH, and other agencies, including evidence synthesis approaches and economic models
• HTA submissions to ICER, NICE, CADTH, and other agencies, including evidence synthesis approaches and economic models
• Value proposition and key message development and testing
• Advanced analytics consulting
• HTA policy consulting
• Access-related reimbursement analysis
• HEOR strategy and health economic modelling
• Value-based contracting strategy

In addition to our strategic services, we offer two novel products integral to developing a comprehensive understanding of competitive reimbursement landscape.